Quantum News
Sign InSign Up
Back to News
research

Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Collegium Pharmaceutical announced its acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics in March 2026 to expand its ADHD portfolio and accelerate growth. The deal includes all relevant corporate subsidiaries, significantly strengthening Collegium’s position in the ADHD market, as highlighted by CEO Vikram Karnani during an investor call. AZSTARYS is expected to complement Collegium’s existing ADHD products, offering a differentiated treatment option for patients and physicians, per Chief Commercial Officer Scott Dreyer. Financial details were discussed by CFO Colleen Tupper, with the acquisition framed as a strategic move to drive long-term revenue growth and market share expansion. The company cautioned that forward-looking statements involve risks, as outlined in SEC filings, with future results potentially differing from current projections.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (19).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.05K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth March 19, 2026 9:00 AM EDT Company Participants Ian KarpVikram Karnani - CEO, President, Executive VP & DirectorScott Dreyer - Executive VP & Chief Commercial OfficerColleen Tupper - Executive VP & CFO Conference Call Participants Yuchen Ding - Jefferies LLC, Research DivisionLeszek Sulewski - Truist Securities, Inc., Research DivisionBrandon Folkes - H.C. Wainwright & Co, LLC, Research DivisionDavid Amsellem - Piper Sandler & Co., Research DivisionSerge Belanger - Needham & Company, LLC, Research Division Presentation Operator Greetings, and welcome to the Collegium Pharmaceutical Investor Call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ian Karp, Head of Investor Relations at Collegium. Thank you. You may begin.

Ian Karp Great. Thanks so much, and welcome to Collegium Pharmaceutical investor call to discuss the acquisition of AZSTARYS and all relevant corporate subsidiaries from Corium Therapeutics, which significantly expands our position in ADHD. I'm joined today by Vikram Karnani, our Chief -- our President and Chief Executive Officer; Scott Dreyer, our Chief Commercial Officer; and Colleen Tupper, our Chief Financial Officer, who will be available for the Q&A portion of today's call. Before we begin, we want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties as detailed in the company's periodic reports filed with the SEC. Our future results may differ materially from our current expectations discussed today. Our press release and this call will include discussion of certain non-GAAP information, and you can

Read Original

Tags

drug-discovery
quantum-investment

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.